During the past few years, there has been more research related to sleep disturbances in patients with IPF and their possible role in sleep and overall life quality, disease progression, and outcome.
"Even though the community of researchers doing sensitive work has the same needs as those doing unrestricted research, the absence of a peer-reviewed publication … impedes the quality and progression of sensitive science," wrote JSCoRE co-editor William Brad Martinin of the U.S. National Security Agency and colleagues in a poster on the journal's origins that they presented at a meeting last year.
We investigated the association between outdoor air quality and progression of subclinical atherosclerosis (common carotid artery intima-media thickness, CIMT).
However, little is known at present about the relation between poor sleep quality and progression of atherosclerosis in patients with T2DM.
These evolving technologies aim to achieve more hyaline cartilage repair of high quality, faster progression of cartilage repair rehabilitation with quicker return to sports and more consistent durability of high-impact sports participation.
The Quality Adjusted progression free survival (PFS) (mean, (95% credibility interval)) was 5.2 months (4.5; 5.8) for Gem/Cis, 5.3 months (4.6; 6.1) for Pem/Cis; 4.9 months (4.4; 5.5) for Pac/Carb and 8.3 (7.0; 9.9) for gefitinib.
Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC.
62 In the analysis, the authors found the incremental improvement in quality-adjusted progression free survival days (QAPFSD) favored XELOX over FOLFOX4 in both first- and second-line settings.
The average cost per quality-adjusted progression-free survival ranged from Can$31,220 for vinorelbine to Can$110,072 for docetaxel.
We estimated mean quality-adjusted progression-free survival days (QAPFSD), considering adverse events and patient preference for chemotherapy regimens.
